An announcement from Akeso, Inc. ( (HK:9926) ) is now available. Akeso, Inc. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ...

(9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China's National ...

HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in ...

Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately $250 million USD through a share placement. This offering has earned notable ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed as the "DeepSeek moment" for China's drug industry, as biotech emerges ...

Summit Therapeutics SMMT reported second-quarter 2025 loss per share of 76 cents, much wider than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company had incurred a ...

Akeso, Inc., a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines, has ...

Akeso Medical Holdings and its clinic partners are now offering services in Southern California, with plans to rapidly expand into other markets. Investors backing the company are led by Kain ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration ...

Akeso’s bispecific antibody improved overall survival in first-line patients with severe gastric cancer or gastroesophageal junction adenocarcinoma in a phase 3 trial, acing the primary endpoint.

According to Akeso, the new approval means that the drug can offer patients continuous immunotherapy options across all stages of NPC, whether it is first line therapy or third-line treatment.